Literature DB >> 16288441

Hypercholesterolemia and LDL apheresis.

F Morelli1, P Carlier, G Giannini, M C De Luigi, A M Dejana, M R Ruzzenenti.   

Abstract

Several trials have assessed the link between low-density lipoprotein cholesterol (LDL) and the development of coronary heart disease (CHD). LDL apheresis provides an effective role in treating patients with familial hypercholesterolemia (FH) and in preventing the progression of coronary artery disease (CAD). Five different techniques of LDL apheresis are in current use: immunoadsorption (IMA), dextran sulphate-cellulose adsorption (DSA), heparin extracorporeal LDL precipitation system (HELP), double filtration plasmapheresis (DFPP) or lipidfiltration and direct adsorption of lipoprotein using hemoperfusion (DALI). All methods are efficient,but their cost restricts LDL apheresis to the treatment of FH. Indications could include other diseases, but controlled trials are still lacking.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288441     DOI: 10.1177/039139880502801010

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  3 in total

Review 1.  Current topics in therapeutic plasmapheresis.

Authors:  Takeshi Nakanishi; Naoki Suzuki; Takahiro Kuragano; Yasuyuki Nagasawa; Yukiko Hasuike
Journal:  Clin Exp Nephrol       Date:  2013-07-26       Impact factor: 2.801

2.  Low-density lipoprotein apheresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01

3.  The Effect of Plasma Triglyceride-Lowering Therapy on the Evolution of Organ Function in Early Hypertriglyceridemia-Induced Acute Pancreatitis Patients With Worrisome Features (PERFORM Study): Rationale and Design of a Multicenter, Prospective, Observational, Cohort Study.

Authors:  Longxiang Cao; Jing Zhou; Mingzhi Chen; Tao Chen; Man Liu; Wenjian Mao; Jiyan Lin; Donghuang Hong; Weijie Yao; Yi Sun; Kaixiu Qin; Feng Guo; Yun Zhou; Qinghai Jiao; Yingjie Chen; Gang Li; Bo Ye; Lu Ke; Zhihui Tong; Yuxiu Liu; Weiqin Li
Journal:  Front Med (Lausanne)       Date:  2021-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.